The global biosimulation technology market is expected to grow at a lucrative rate over the forecast period owing to the increasing use of pharmacokinetic and pharmacodynamic (PKPD) methods during the preclinical drug development process. The other drivers of this market are increasing expenditure on healthcare, time and cost spent on drug development and discovery, failure of drugs during development stages, less production of output, upgraded modeling and simulation tools, and the growing importance of advanced technologies. Manufacturers are now focusing on the biosimulation technology to reduce the wastages during the drug development stage. The pharmacokinetics process describes the drug course concentration-time, with the help of body fluids.
The Biosimulation technology market is segmented on the basis of application into drug development and drug discovery. Drug development is further divided into preclinical testing, clinical trials, and patient validation. Among these pre-clinical testing holds the larger market share. This stage deals with all the researches which are done before the clinical trials phase. These details are further used in the next process. The main purpose of this phase is to produce a safe dose for human beings, without any flaws. Drug discovery is further segmented into lead identification, target identification, lead optimization, and target validation. Among these, target identification holds a larger market share. Protein structure prediction is the 3D structure of protein, which is extracted from the amino acid sequence of the drugs.
North America is dominating the market followed by Europe, due to the presence of strong research and development, increasing advanced technologies and various government initiatives and programs along with the presence of huge numbers of manufactures. Most of the domestic and international players are focusing on the emerging market, such as China and India, as these are lucrative market and are expected to grow in the biosimulation technology market.
The major market players of the biosimulation technology market are Accelyrs, Inc., Chemical Computing Group, Molecular Knowledge Systems, Inc., Rhenovia Pharma S.A.S, Simulations Plus, Inc., Certara, Simulations Plus, Inc., Advanced Chemistry Development (Acd/Labs), and Insilico Biotechnology Ag.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.